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Summary
Background Many people with dementia living in care homes have distressing and costly agitation symptoms. 
Interventions should be efficacious, scalable, and feasible.
Methods We did a parallel-group, cluster-randomised controlled trial in 20 care homes across England. Care homes 
were eligible if they had 17 residents or more with dementia, agreed to mandatory training for all eligible staff and the 
implementation of plans, and more than 60% of eligible staff agreed to participate. Staff were eligible if they worked 
during the day providing face-to-face care for residents with dementia. Residents were eligible if they had a known 
dementia diagnosis or scored positive on screening with the Noticeable Problems Checklist. A statistician independent 
of the study randomised care homes (1:1) to the Managing Agitation and Raising Quality of Life (MARQUE) 
intervention or treatment as usual (TAU) using computer-generated randomisation in blocks of two, stratified by type 
of home (residential or nursing). Care home staff were not masked to the intervention but were asked not to inform 
assessors. Residents with dementia, family carers, outcome assessors, statisticians, and health economists were 
masked to allocation until the data were analysed. MARQUE is an evidence-based manualised intervention, delivered 
by supervised graduate psychologists to staff in six interactive sessions. The primary outcome was agitation score at 
8 months, measured using the Cohen-Mansfield Agitation Inventory (CMAI). Analysis of the primary outcome was 
done in the modified intention-to-treat population, which included all randomly assigned residents for whom CMAI 
data was available at 8 months. Mortality was assessed in all randomly assigned residents. This study is registered 
with the ISRCTN registry, number ISRCTN96745365.
Findings Between June 14, 2016, and July 4, 2017, we randomised ten care homes (189 residents) to the MARQUE 
intervention and ten care homes (215 residents) to TAU. At 8 months, primary outcome data were available for 
155 residents in the MARQUE group and 163 residents in the TAU group. At 8 months, no significant differences in 
mean CMAI scores were identified between the MARQUE and TAU groups (adjusted difference –0·40 [95% CI 
–3·89 to 3·09; p=0·8226]). In the intervention care homes, 84% of all eligible staff completed all sessions. The mean 
difference in cost between the MARQUE and TAU groups was £204 (–215 to 623; p=0·320) and mean difference in 
quality-adjusted life-years was 0·015 (95% CI –0·004 to 0·034; p=0·127). At 8 months, 27 (14%) of 189 residents in the 
MARQUE group and 41 (19%) of 215 residents in the TAU group had died. The prescription of antipsychotic drugs 
was not significantly different between the MARQUE group and the TAU group (odds ratio 0·66; 95% CI 0·26 to 1·69, 
p=0·3880).
Interpretation The MARQUE intervention was not efficacious for agitation although feasible and cost-effective in 
terms of quality of life. Addressing agitation in care homes might require resourcing for delivery by professional staff 
of a more intensive intervention, implementing social and activity times, and a longer time to implement change.
Funding UK Economic and Social Research Council and the National Institute of Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Agitation or purposeless activity, which includes 
restlessness, pacing, repetitive vocalisations, and verbally 
or physically aggressive behaviours,1,2 is one of the most 
common neuropsychiatric symptoms in dementia.3,4 
Such behaviours are unpleasant for the person with 
dementia,1 can cause family distress and subsequent 
inability to continue to care at home,5 can precipitate care 
home admission and, in care homes, are strongly 
associated with quality of life.6 Agitation accounts for 
about 12% of dementia health and social care costs, and 
increases costs for care home residents.7
Most care home residents have dementia and complex 
needs, and around 50% of individuals with moderate or 
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severe dementia have clinically significant agitation.8 
Agitation is associated with dementia severity and might 
also be associated with physical conditions (such as 
untreated or undertreated delirium or pain or medication 
side-effects), or other unmet needs such as boredom and 
social isolation. Activities in care homes are not necessarily 
attended by individuals with agitation.6,9,10 Intensive 
multicomponent interventions in which physical, social, 
or occupational activities are implemented, and staff are 
trained to ensure people with dementia and agitation 
participate, had some success in reducing agitation in care 
home residents with dementia immediately after the 
intervention,10–13 with a similar magnitude of effect to 
antipsychotic medication, but without the associated side-
effects.14,15 However, such interventions might not be 
scalable or cost-effective, since they require specialist 
professional training of care home staff, ongoing 
supervision to deliver person-centred care and improve 
communication, physical problems to be addressed, and 
the implementation of social or other activities, such as 
positive sensory experiences. Interventions are often 
difficult to implement.16 It is unclear whether interventions 
can lead to cultural change that becomes embedded in 
care home practices, so that effects persist or even increase 
after the intervention. We therefore developed and piloted 
a manual-based intervention (Managing Agitation and 
Raising Quality of Life in dementia; MARQUE) 
comprising six sessions, delivered by supervised non-
clinical psychology graduates, on the basis of evidence 
about what works for people with dementia and agitation, 
Research in context
Evidence before this study
Our 2014 systematic review of randomised controlled trials of 
non-pharmacological interventions for agitation in people with 
dementia found activities, structured music therapy, and sensory 
interventions provided immediate but not lasting benefit. 
However, benefits of staff training in communication skills lasted 
months. In our update in May 2018, we searched PsycINFO and 
Embase for randomised controlled trials published between 
June 12, 2012, and May 15, 2018, that reported on care home 
interventions targeting agitation for people with dementia of 
any severity and how to sustain an intervention, using the terms: 
(agitation OR restless* OR irrita* OR aggression OR “aberrant 
motor behav*” OR “psychomotor activity” OR “challenging 
behav*” OR pacing OR sundowning OR wander* OR “walking 
about” OR “safe walking”) AND (dement* OR alzheimer OR 
“vascular dement*” OR “pick’s disease” OR huntington OR 
creutzfeldt OR cjd OR binswanger OR lewy) AND (“randomised 
control* trial*” OR RCT”), with no language restrictions. 
Our search identified 49 trials, of which 16 measured agitation as 
an outcome. Three studies reported clinically significant 
reductions in agitation. Successful interventions were intensive 
and multicomponent. The first intervention comprised staff 
training, increased social interaction, antipsychotic review, 
physician review of medical history, all medications and physical 
examination, assessment of pain, a doctor and nurse-led 
reflective case conference developing individualised treatment 
plans using a problem-solving model and a 3 h educational 
lecture, and role play for 8–12 weeks. This intervention reduced 
agitation at the end of the intervention. The second intervention 
included training and support of care home staff by a physician 
and specialist nurse for two 4 h blocks on behavioural symptoms 
in dementia using standardised assessments, 
non-pharmacological and pharmacological interventions, case 
conferences using standardised case vignettes, and activities 
delivered twice per week by activity co-coordinators or 
occupational therapists, for residents not already attending. 
This intervention was effective at 10 months for agitation. 
The third intervention combined training for staff and managers 
in person-centred care and the promotion of tailored 
person-centred activities and social interactions by a psychologist 
or occupational therapist working in the home for a month. 
Further training was provided for two champions (one training 
day per month) with coaching, supervision, and regular review 
with the therapist during the 9 month period. The intervention 
also included, if appropriate, triggering doctor’s review of 
antipsychotic medications, and for individuals who did not 
participate in activities, implementation of activities. 
This intervention was effective at 9 months. One intervention 
was costed, but no cost-effectiveness analyses were done and we 
identified no reports of intervention effects being sustained. 
A separate systematic review found that interventions were 
sustained by interactive training, individual staff support after 
group training, retention of training materials, incorporating 
interventions into routine care, and nearly all staff attending.
Added value of this study
Our Managing Agitation and Raising Quality of Life (MARQUE) 
intervention, which comprised six sessions of staff training, 
was less intensive than some multicomponent interventions 
that have had positive outcomes and was primarily delivered by 
non-clinical staff. The intervention did not reduce agitation or 
affect secondary outcomes. The cost-effectiveness analysis 
estimated effectiveness using improvements in quality-adjusted 
life-years (QALYs) and found that the costs for QALY 
improvements were less than the National Institute for Health 
and Care Excellence threshold and thus the intervention was 
deemed cost-effective.
Implications of all the available evidence
Evidence suggests that intensive, multicomponent, 
psychosocial interventions delivered by specialists to reduce 
agitated behaviour in people with dementia in care homes can 
be successful, but no evidence exists for the efficacy of less 
intensive, specialist, and costly interventions such as MARQUE. 
Helping people with dementia and agitation in care homes 
requires well-resourced interventions.
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and what enables interventions to become integrated into 
care practice long term.17,18 This trial aimed to assess 
whether the MARQUE intervention reduced agitation in 
residents with dementia after 8 months compared with 
treatment as usual (TAU).
Methods
Study design and participants
We did a parallel-group, superiority, single-blind, 
cluster-randomised controlled trial that involved 20 care 
homes in England. We restricted recruitment to areas 
that were within 2 h travel distance of our base in London 
(UK). Eligible care homes had no plans to close in the 
following year, were not currently participating in an 
intervention study, and agreed, if randomised to the 
intervention, to allow eligible staff to attend mandatory 
training sessions and follow-up supervision during 
shifts, to train two staff champions to facilitate implemen-
tation (to promote shared ownership and because of 
possible staff turnover), and to change management 
procedures to integrate new techniques into care. Eligible 
staff worked during the day, providing face-to-face care to 
residents with dementia. Care homes were excluded 
before random isation if fewer than 60% of eligible staff 
consented or if fewer than 17 potential residents with 
dementia lived at the care home.
All residents with dementia were eligible for the study. 
Care home managers identified residents with a known 
diagnosis of dementia and we screened other residents 
for probable dementia using the Noticeable Problems 
Checklist,19 which has been validated against clinical 
diagnosis.19,20 Care home staff approached residents and 
relatives. Staff identified residents with capacity to consent 
to the study, and researchers assessed their capacity using 
the Mental Capacity Act 200521 criteria. If residents lacked 
capacity to consent, we consulted the family carer or, if 
none were available, a professional consultee who knew 
the resident well to give written informed consent. We 
asked the care home manager to nominate staff who knew 
a resident well to give proxy ratings and also interviewed a 
consenting primary family carer if they saw the resident at 
least monthly. Full inclusion and exclusion criteria for 
care homes, residents, paid carers, and family carers are 
shown in the appendix.
The study was approved by the National Research Ethics 
Service Committee London (reference 14/LO/0697). The 
trial is registered with the ISRCTN registry, number 
ISRCTN96745365. The study protocol is available online 
and is included in the appendix.
Randomisation and masking
A statistician independent of the study randomised care 
homes (1:1) to the MARQUE intervention or TAU using 
a computer-generated randomisation sequence; care 
homes were randomised in blocks of two, stratified by 
type of home (residential or nursing). The random-
isation list was held by Clinical Trials Unit staff who 
communicated pairs of allocations to the trial manager 
(AL) as required. Care home staff were not masked to the 
intervention but were asked not to inform assessors. 
Residents with dementia, family carers, assessors who 
collected data, statisticians and health economists were 
masked to allocation until the data were analysed. 
Trained psychology graduates worked as MARQUE 
facilitators and assessors in two separate teams to 
maintain masking; one group was allocated to complete 
baseline and follow-up assessments for an individual 
home and the other group to facilitate and deliver the 
intervention if randomly assigned to the intervention. 
We provided clear, repeated instructions to researchers 
and care home staff not to discuss treatment allocation 
and to put away materials associated with the 
intervention.
Procedures
We developed MARQUE, a six-session manual-based 
intervention, followed by an implementation and 
supervision period (panel), based on our systematic 
review of strategies to reduce or prevent agitation for 
people with dementia in care homes,11 qualitative inter-
views with care home staff about their understanding 
of agitation and what facilitated use of successful 
strategies,23 cross-sectional and longitudinal data on 
determinants of agitation in care homes,6,24 a systematic 
review of components and strategies for successful 
implementation of psychosocial interventions in care 
homes,17 and coproduction with stakeholders. We ran 
three focus groups with family carers of people with 
dementia who had experienced agitation and or lived in a 
care home, two before developing the intervention and 
one after, about what should be in the intervention. 
Additionally, we showed the draft manual to seven staff 
working in differing roles in four care homes and asked 
them to comment on the design, layout, content, and 
structure of the manual. Managers were asked about the 
practicality of delivering the intervention. We also sought 
feedback from a range of professionals and other 
stakeholders from the MARQUE steering group and our 
community of interest group (a network of academic 
researchers, policy makers, community stakeholders, 
and patient and public involvement representatives). In 
addition to presenting the overview of the intervention to 
the community of interest group, we consulted six of the 
members individually (a geriatrician, a sociologist, a 
research nurse, an occupational therapist, an academic 
psychologist, and a clinical psychologist) to get feedback. 
The six members suggested changes in formatting and 
language and requested more focus on risk, pain, and 
illness. We then piloted the intervention in one care 
home, and made changes after feedback from both 
facilitators and care home staff before testing it in the 
main trial. The changes included modification of the 
interaction level in some parts of the manual, making 
between-session tasks more specific, checking with 
For the study protocol see  
http://www.isrctn.com/
ISRCTN96745365
See Online for appendix
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participants that they had understood tasks, and 
simplifying some of the content. Additionally, the 
pleasant events section was restructured and greater 
emphasis was placed on how pleasant events did not 
need to be time and resource intensive stand-alone 
activities, but could be part of routine care. We also added 
more detail to the manual regarding what the supervision 
and troubleshooting period would involve and placed 
more emphasis on the supervision period during 
training sessions. We arranged to meet with managers 
and cham pions halfway through the intervention 
sessions to review and plan follow-up supervision and 
troubleshooting.
We delivered a multidisciplinary training programme 
for the MARQUE facilitators. Each facilitator was 
required to be signed off from a competency checklist as 
ready to deliver the intervention before initial delivery.
Two facilitators delivered the intervention to groups of 
up to 12 care home staff (care assistants, nurses, and 
activities coordinators). Managers were encouraged to 
attend training to promote the idea that they, as well as the 
care staff, were part of implementing the intervention, 
and to support with implementation of strategies. We 
delivered sessions several times in each home to ensure 
groups were kept to a size that enabled interaction and the 
attendance of all eligible staff. For staff who missed a 
session, we arranged a time to deliver an individual 
abbreviated version. We offered care homes reimburse-
ment for staff cover to allow staff to attend sessions and 
worked closely with managers to facilitate attendance and 
engagement with the intervention.
A clinical psychologist (PR) supervised facilitators in 
two groups to maintain masking with additional indi-
vidual support as needed. Facilitators were encouraged to 
be empathetic, adhere to the intervention, work with staff 
to reflect on and try different strategies, not be dis-
couraged as change might be slow, and encourage staff to 
communicate and use the whole team rather than 
respond in isolation. The staff were encouraged to raise 
any challenging interactions and report any potentially 
abusive behaviour. We monitored intervention fidelity 
using checklists, which were tailored to the content of 
each session. The checklists were used to rate whether 
the most important components of every session were 
delivered, on a Likert scale from 1 (not at all) to 5 (very 
focused) for each item. The checklists also included four 
items to rate process factors (keeping to time, keeping 
the group focused on the manual, keeping the group 
engaged in the session, and managing group dynamics). 
All items were summed to give an overall score out of 40 
for the individual facilitator. Facilitators recorded one 
training session per training group per home, which the 
trial manager selected randomly for review by researchers 
who had not delivered the intervention.
The manualised sessions are described in the panel. 
All materials were retained by attendees. MARQUE 
incorporated a variety of heuristics designed to become 
part of the team working, specifying ideas to try and how 
to implement them. The heuristics included a board 
game (Call to Mind) played with residents to find what 
they like to do, a CD or mp3 of stress reduction exercises 
for staff, pleasant events tick lists, and a decision making 
model to manage agitation adapted for UK practice 
(Describe, Investigate, Create, Evaluate).21 Each session 
included interactive group tasks, talking points, 
summaries, and some discussion with staff about earlier 
sessions, finishing with a relaxation session. We asked 
staff to try out strategies and practice relaxation exercises 
between sessions. In the final session, staff developed 
specific, measurable, attainable, relevant, and time-based 
Panel: Managing Agitation and Raising Quality of Life in dementia manualised 
sessions
Sessions 1–5 all included one or two key topics for discussion, a specific plan or activity to 
try out between sessions, a stress reduction exercise with an accompanying CD or mp3 
file, and a record form for staff to complete for monitoring progress between sessions. 
During each session, the participants shared examples from their practice to ensure that 
the intervention was individually focused and relevant.
Session 1: Getting to know the person with dementia
This session included psychoeducation about dementia and staff experiences of managing 
agitation, including what works. It also introduced the key theme that getting to know 
and understand the person with dementia can help staff to manage and prevent agitation 
from occurring. The session included a game to find out what the person with dementia 
enjoyed doing and included a focus on managing the stress that caring can bring.
Session 2: Pleasant events
This session focused on the importance of pleasant events for residents. It included a 
focus on how to plan for and include residents with severe dementia and how to build 
activities into day-to-day care. The session introduced the idea that even small 
interactions could be pleasant events.
Session 3: Improving communication
This session discussed communicating with people with dementia, with a particular focus 
on how to respond when residents are distressed. It also included discussion and exercises 
on effective communication within the team and with relatives.
Session 4: Understanding agitation
This session introduced the Describe, Investigate, Create, Evaluate approach,22 focusing on 
describing and investigating episodes of agitation. The content is framed in terms of 
recognising and understanding the unmet needs of residents with agitation.
Session 5: Practical responses and making a plan
This session focused on creating strategies to manage agitation, including practical and 
environmental changes and when to ask for additional help. The session also introduced 
the importance of building these strategies into a plan that can be evaluated.
Session 6: What works? Using skills and strategies in the future
This session recapped on earlier sessions and focused on what staff had found useful and 
what worked. It included the development of a specific action plan, individual to each 
home, to enable staff to continue to use helpful strategies and approaches and to inform 
the supervision phase of the intervention.
Supervision process
Team members met with the care home manager to ensure they agreed with the plan and 
set up supervision and troubleshooting meetings.
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(SMART) action plans of useful strategies for their care 
home and residents. Facilitators discussed and refined 
the plans for each care home with the home manager to 
ensure they were supportive and that plans were realistic 
and deliverable, and to discuss practicalities of how best 
to deliver long-term support. PR offered monthly clinical 
supervision to care home staff alternating with the 
facilitators who visited monthly to support staff to 
implement their action plans.
Residents, relatives, carers, and staff recruited to the 
study had data collected at baseline and at 8 month follow-
up assessments. We also recorded sociodemo graphic 
characteristics of eligible non-consenting residents at 
baseline. Assessors completed interviews with residents 
and staff in a private room at the care home. Family carers 
chose the interview location, usually a private room at 
the care home. We recorded socio demographic details 
of residents and staff at baseline (sex, staff role at care 
home, years working in current home) and care home 
characteristics, including size and whether the home was 
residential or nursing.
Outcomes
The primary endpoint was agitation score at 8 months, 
measured using the Cohen-Mansfield Agitation 
Inventory (CMAI).2 The CMAI assesses the frequency of 
29 agitated behaviours, each scored on a seven-point 
Likert scale from 1 (never) to 7 (several times an hour), 
and summed to give a total score, ranging from 29 to 203.
Resident data for the following secondary outcomes 
were obtained at baseline and 8 month follow-up through 
proxy interviews with staff: agitation symptoms (CMAI) 
and clinically significant agitation (defined as CMAI 
score >45);6,25 reduction in neuropsychiatric symptoms 
(measured using the Neuropsychiatric Inventory26) with 
12 symptoms scored in the previous 4 weeks, with the 
total score ranging from 0 to 144, whereby higher scores 
indicate worse symptoms; dementia-specific health-
related quality of life (measured by the DEMQOL-
Proxy),27 with 31 items scored from 1 (a lot) to 4 (not at all) 
giving a total score ranging from 31 to 124 whereby a 
higher score indicates better quality of life; service use 
using the Client Services Receipt Inventory28 modified 
for care homes to cost health and social care services and 
carer time; cost of manual training and intervention; and 
generic health-related quality of life using the proxy-rated 
European quality of life five dimensions questionnaire 
(EQ-5D-5L),29 with five dimensions (mobility, self-care, 
usual activities, pain or discomfort, and anxiety or 
depression), scored from 1 (no problems) to 5 (extreme 
problems), summarised using a 5 digit number that can 
be converted into a preference weight.
Additional outcomes for residents were dementia 
severity, assessed using the Clinical Dementia Rating,30 a 
widely used measure of global dementia severity, scored 
from 0 (none) to 3 (severe), and psychotropic medication 
prescribed in the previous month. Additional out comes 
for staff were the Maslach Burnout Inventory,31,32 
which is a validated measure with three subscales 
(emotional exhaustion, depersonalisation, and personal 
accomplishment) with items scored as 0 (never) to 6 (every 
day) and summed to provide subscale scores; the sense of 
competence in dementia (SCID)33 scale, which provides a 
self-report measure of subjective competence in care 
staff, with four subscales (professionalism, building 
relationships, care challenges, and sustaining personhood) 
whereby higher scores indicate greater competence; and 
the Staff Tactics Scale,34 which uses a Likert scale to 
measure observed acts of possibly abusive and positive 
behaviours committed by staff or observed in other staff in 
the previous 3 months.34 The Staff Tactics Scale is anony-
mous and scores range from 0 (never) to 4 (all the time) 
and a score of 2 or more was defined as caseness. We 
collected questionnaires from each care home and we 
informed the care home manager if we identified physical 
abuse.
We did not collect safety outcomes separately, but did 
record mortality and antipsychotic prescribing.
Statistical analysis
The sample size was calculated using inflation by the 
design effect of the numbers required for analysis in an 
individually randomised parallel group trial.35 The 
calculation used the observed effect size (0·5) of a 
standardised intervention in reducing emergent or 
symptomatic agitation in care home participants.11 To 
detect this clinically significant difference36 with 
90% power at the 5% significance level would require 
54 residents per group for an individually randomised 
design based on the use of analysis of covariance to adjust 
for baseline (correlation 0·6).37 We aimed to randomise 
20 care homes, allowing for the possibility that two homes 
might drop out. With a sample size of 18 care homes and 
assuming an intra cluster correlation coefficient of 0·087,38 
an average of 12 residents would be needed per cluster. To 
allow for up to 30% loss to follow-up, we aimed to recruit 
17 residents from each care home. Statistical analyses 
were done in accordance with a predefined statistical 
analysis plan using Stata (version 14). We summarised 
differences in characteristics between eligible consenting 
and non-consenting residents. We reported sociodemo-
graphic and baseline clinical characteristics for each 
randomised group and adherence to the intervention as 
number of sessions delivered in each home, number of 
staff attending, number of sessions each member of staff 
attended, and fidelity scores. We calculated the proportion 
of care homes in which more than 80% of staff attended 
all six sessions (group sessions or catch up sessions) and 
the intracluster correlation coefficient for the primary 
outcome. We imputed DEMQOL scores using mean 
imputation when more than 50% of data was present, but 
did not impute any other data.
We summarised CMAI scores at 8 months by 
treatment group and compared them using a two-level 
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mixed effects linear regression model allowing for care 
home clustering. The model was adjusted for baseline 
CMAI score, type of care home (residential vs nursing), 
and baseline severity of dementia (Clinical Dementia 
Rating). Similar analyses were done for the following 
secondary outcomes and prespecified additional 
outcomes: total Neuropsychiatric Inventory score, 
DEMQOL-Proxy, SCIDS, Maslach Burnout Inventory, 
and Staff Tactics Scale. We used mixed effects logistic 
regression to assess clinically significant agitation 
(CMAI scores >45) and use of psychotropic drugs. 
Although Staff Tactics Scale data were anonymous, other 
care home level factors were included in models for this 
outcome; thus we could identify the care home at which 
staff worked. Reasons for missing outcome data were 
examined for each randomised group. We compared 
characteristics of residents with and without missing 
outcome data using mixed effects logistic regression 
models (and identified characteristics predicting 
missingness). Model residuals were checked using 
normal plots and plots of fitted values against residuals. 
The primary outcome was assessed in the modified 
intention-to-treat population, which included all 
randomly assigned residents for whom CMAI data was 
available at 8 months. Mortality was assessed in all 
randomly assigned residents.
We did the following sensitivity analyses to estimate the 
treatment effect for the primary and secondary outcomes: 
unadjusted treatment effect estimate (from mixed effects 
models allowing for clustering); additional adjustments for 
baseline factors that predicted missingness of outcomes; 
and adjustment for imbalances in baseline characteristics. 
After checking model residuals we found some non-
normality for CMAI and the Neuropsychiatric Inventory, 
which have positively skewed distributions. We did 
sensitivity analyses for these outcomes refitting our model 
using quantile regression.
The cost of the MARQUE intervention included the 
cost of training the therapists, and the cost of delivery of 
the intervention (appendix). Hourly costs for therapists 
and care home staff were taken from the Personal Social 
Services Research Unit.39
Data regarding health-care service use was collected 
using the Client Services Receipt Inventory for the 
previous 4 months and medication prescriptions from 
medication charts. Unit costs from published sources37, 40,41 
were attached to each resource item. The economic 
analysis was done from the health-care cost perspective. 
All costs are reported in pounds sterling at 2015–16 prices.
Quality-adjusted life-years (QALYs) were calculated as 
the area under the curve adjusting for baseline 
differences over 8 months between the MARQUE and 
TAU groups. QALYs were calculated using the EQ-5D-5L. 
We used multivariate imputation by chained equation for 
missing data, generating 20 imputed data sets. For each 
dataset, we used non-parametric bootstrapping (with 
1000 replications) to resample observations with 
replacements. The bootstrap results were combined to 
calculate the mean values for costs and utilities and the 
SEs for the imputed values were used to calculate 
95% CIs. We calculated the incremental cost per QALY 
gained and the probability of cost-effectiveness of 
intervention versus TAU for a range of values of 
willingness to pay for each QALY gained.
We did a sensitivity analysis including the cost of the 
intervention for all residents living in care homes 
randomly assigned to the intervention since the 
intervention was delivered to staff and therefore affected 
the whole care home. 
Role of the funding source
The funders and sponsors of the study had no role 
in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between June 14, 2016, and May 3, 2017, we approached 
33 care homes, of which 28 homes were eligible, and 
20 (71%) of 28 eligible homes were recruited. Of the 
33 care homes approached, seven did not respond after 
Figure 1: Recruitment and follow-up of residents
189 residents at 10 care homes allocated to
          MARQUE
20 care homes and 404 residents randomised 
906 residents assessed for eligibility
34 lost to follow-up 
 27 died 
 6 left care home
 1 admitted to hospital
              
215 residents at 10 care homes allocated to
         treatment as usual
155 assessed at 8 month follow-up and
         analysed for primary outcome
163 assessed at 8 month follow-up and
         analysed for primary outcome  
52 lost to follow-up 
 41 died
  7 left care home
 3 full data unavailable
 1 unknown
502 excluded
 269 declined to participate 
 113 home unable to contact
 64 researcher unable to contact
 30 died
 7 left care home
 7 unknown
 4 admitted to hospital 
 3 too unwell 
 3 no eligible informant identified 
 2 consent received too late 
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initial contact, four had too few residents with dementia, 
one was involved in another intervention study, and one 
could not participate because the care home management 
refused permission. By June 4, 2017, we had randomised 
20 care homes. Of the 20 randomised homes, 15 were 
private and five were charity-run; eight were residential, 
and 12 were nursing or mixed nursing and residential 
homes. Care Quality Commission ratings for consented 
homes are shown in the appendix. 767 eligible residents 
were identified, of whom 410 (53%) consented to take 
part. Six participants withdrew between consent and 
randomisation; thus, 404 (53%) eligible residents were 
randomly allocated. Participating residents had similar 
characteristics (age, sex, dementia diagnosis) to non-
participants; however, staff deemed 59 (15%) of 404 of 
participants to have capacity to consent compared with 
30 (8%) of 363 non-participants. Ten care homes 
(189 residents) were assigned to the MARQUE inter-
vention and ten care homes (215 residents) to the TAU 
group. A mean of 20·2 residents (SD 3·8) were recruited 
in each care home. No participating care homes withdrew 
from the study. Figures 1 and 2 show resident and staff 
flow through the study. The flow of family carers is shown 
in the appendix.
Most residents were female (mean age 86 years [SD 8]), 
and 90% spoke English as their first language (table 1). 
Mean CMAI score at baseline was 42 (SD 16) in the 
MARQUE group and 44 (15) in the TAU group; 59 (31%) 
of 189 residents in the MARQUE group and 81 (39%) of 
210 patients in the TAU group had clinically significant 
agitation. Demographic character istics of the 492 care 
home staff and baseline burnout, SCID, and Staff Tactics 
Scale scores are shown in table 2. Most staff were women 
(mean age 44 years [SD 12]) and 74 (31%) of 241 in the 
MARQUE group and 112 (45%) of 248 in the TAU group 
were white; 115 (48%) of 242 staff and 124 (50%) of 
248 staff spoke English as their first language.
At baseline, we obtained consent from 129 family 
carers in the MARQUE group and 163 in the TAU group. 
39 (30%) of 129 carers in the MARQUE group and 
51 (31%) of 163 carers in the TAU group were men (mean 
age 60 years [SD 12] vs 62 years [9]). Family carers were 
most often the children of the residents with dementia. 
The median number of visits made per month was 9 
(IQR 4–13) for the MARQUE group and 9 (IQR 4–14) for 
the TAU group.
Each facilitator delivered sessions in a median of six 
homes (range one to seven) and seven of eight 
facilitators were women. The facilitators delivered a 
mean of 3 sessions per week (range 2–4) with a mean of 
27 staff (range 17–41) trained in each home. The mean 
eligible staff attendance at all six sessions across the 
intervention care homes, including catch-ups, was 
84% (range 67–100). Of the ten care homes assigned to 
the MARQUE intervention, more than 80% of staff 
attended all six sessions in six homes, 70–80% of 
staff attended all six sessions in three homes, and 
67% attended all six sessions in one home. One session 
per training group was recorded (n=32) and the mean 
fidelity score for all recorded sessions was 37·7 out of 40 
(range 34·0–39·3). The median supervision time after 
completion of the six sessions was 640 min 
(IQR 581–885) per care home for 59% of staff that 
attended training; each member of staff received a 
median of 1 supervision session (0–2) after training, and 
newly employed staff received a median of 1 supervision 
session (1–2).
Primary outcome data were collected for 155 (82%) of 
189 residents in the MARQUE group and 163 (76%) of 
215 residents in the TAU group; thus, these residents were 
included in the modified intention-to-treat analysis set. 
The intracluster correlation coefficient was 0·03 (95% CI 
0·00 to 0·20). CMAI scores were not significantly different 
between the two groups at 8 month follow-up (difference 
–0·40, 95% CI –3·89 to 3·09; p=0·8226). Differences in 
CMAI remained non-significant in sensitivity analyses 
controlling for predictors of missingness (resident age, 
resident sex, and family carer sex) and imbalances in 
baseline characteristics (resident sex, resident marital 
status, psychotropic medication) and also in unadjusted 
analyses and quantile regression (table 3).
Figure 2: Recruitment and follow-up of care home staff
243 staff at 10 care homes allocated to
         MARQUE
 
492 enrolled and randomised
913 care home staff assessed for eligibility
53 lost to follow-up 
 49 left care home
 4 ineligible
15  did not complete 8 month 
      follow-up 
 10 absent
 5 unknown
249 staff at 10 care homes allocated to
          treatment as usual
175 completed follow-up measures 179 completed follow-up measures
175 analysed at 8 months 179 analysed at 8 months 
47 lost to follow-up
 42 left care home 
 3 ineligible
 2 too unwell   
23 did not complete 8 month 
      follow-up 
 8 refused
 7 absent 
 5 unknown 
 2 no time 
         1 missing demographic 
            data  
421 excluded 
 341 did not meet inclusion criteria
 49 declined to participate
 29 unknown
 2 researcher error 
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No significant differences in secondary outcomes were 
identified between the two groups in the main or 
sensitivity analyses (table 3). Although the prescription 
of antipsychotic drugs (odds ratio 0·66; 95% CI 
0·26 to 1·69, p=0·3880) and reporting of any abusive 
behaviours (0·67; 0·43 to 1·05, p=0·0790) were lower in 
the MARQUE group than the TAU group, the differences 
were not statistically significant. More staff completed 
the Staff Tactics Scale than were interviewed at follow-up 
(n=356). 8 month interview follow-up data were available 
for 354 (72%) of 492 staff (175 in the MARQUE group 
and 179 in the TAU group). No statistically significant 
differences in Maslach Burnout Inventory or SCID 
overall scores were identified between the two groups 
(table 4).
The total cost of training and delivery of the intervention 
was £41 510 (appendix). Assuming this would be the cost 
required to train and deliver the intervention to the 
189 residents randomly assigned to receive the MARQUE 
intervention, the total cost per resident was £220.
Health and social cost resource use and utility values 
for residents in each group are shown in the appendix. 
The mean total cost per resident in the intervention 
group, including the cost of the MARQUE intervention, 
was £1379 (95% CI 1041 to 1718) compared with £1175 
(917 to 1433) in the TAU group. The mean difference in 
cost between the MARQUE and the TAU groups was 
£204 (–215 to 623; p=0·320).
Non-parametric bootstrapping after multiple imputation 
showed that residents in the MARQUE group gained 
0·346 QALYs (95% CI 0·330 to 0·362) and residents in the 
TAU group gained 0·332 QALYS (0·322 to 0·342) with a 
mean difference of 0·015 QALYs (–0·004 to 0·034), which 
was not statistically significant (p=0·127).
Combining the difference in costs and difference in 
QALYs, the mean incremental cost per QALY gained of 
the MARQUE intervention compared with TAU was 
£14 064. Residents receiving the MARQUE intervention 
accrued a higher cost and gained more QALYs than 
residents in the TAU group, but the differences between 
groups were not significant. The MARQUE intervention 
has a 62% probability of being cost-effective at a willing-
ness to pay of £20 000 and 77% probability of being cost-
effective at a willingness to pay of £30 000 (appendix).
Including all residents living in care homes that 
were allocated to the intervention (n=282), the cost of 
MARQUE intervention per resident would become £147 
(£41 510/282). The mean total cost per resident in the 
MARQUE group would decrease to £1307 (95% CI 
968 to 1646), which remains higher than that in the TAU 
group (£1175). The mean difference in cost between 
groups was £132 (–287 to 551), which was not statistically 
significant (p=0·518). Combining difference in costs and 
QALYs results in an incremental cost-effectiveness ratio of 
£9078. Using this approach, the MARQUE intervention 
has a 73% probability of being cost-effective at a willing-
ness to pay of £20 000 and an 83% probability of being 
Treatment as usual 
(n=215)
MARQUE 
(n=189)
Sex
Men 74 (34%) 41 (22%)
Women 141 (66%) 148 (77%)
Age (years)* 86 (7) 86 (8)
Ethnicity
White 169/207 (82%) 167/186 (90%)
Asian 6/207 (3%) 3/186 (2%)
Black 25/207 (12%) 16/186 (9%)
Other 7/207 (3%) 0/186
First language English 184/205 (90%) 162/178 (90%)
Marital status
Married or partner 42/195 (22%) 30/177 (17%)
Not currently married 153/195 (78%) 147/177 (83%)
Education
None 66/152 (43%) 40/122 (33%)
O levels, GCSEs, NVQ 
(levels 1–3), or A levels†
49/152 (32%) 37/122 (30%)
Degree or postgraduate 24/152 (16%) 31/122 (25%)
Other 13/152 (9%) 14/122 (11%)
Diagnosis of dementia 
pre-study
182/215 (85%) 148/189 (78%)
Dementia severity (Clinical Dementia Rating)
Mild dementia 28/207 (14%) 36/170 (21%)
Moderate dementia 82/207 (40%) 69/170 (41%)
Severe dementia 97/207 (47%) 65/170 (38%)
CMAI score
Mean CMAI score‡ 44 (15) 42 (16)
Median CMAI score‡ 41 (31–52) 37 (29–50)
Clinically significant agitation 
(CMAI >45)
81/210 (39%) 59 (31%)
Aggressive behaviour 17 (8) 17 (8)
Physically non-aggressive 
behaviour§
11 (6) 10 (6)
Verbally agitated¶ 8 (5) 7 (5)
NPI
Mean NPI|| 16 (16) 14 (14)
Mean NPI agitation‡** 2 (3) 2 (3)
NPI agitation 105/212 (49%) 93/188 (49%)
Psychotropic drugs
Any psychotropic drug 107/214 (50%) 75/187 (40%)
Antipsychotics 27/214 (13%) 23/187 (12%)
Antidepressants 77/214 (36%) 52/187 (28%)
Anxiolytic or hypnotic 33/214 (15%) 23/187 (12%)
Data are n (%), n/N (%), mean (SD), or median (IQR). GCSE=General Certificate of 
Secondary Education. NVQ=National Vocational Qualification. 
CMAI=Cohen-Mansfield Agitation Inventory. NPI=neuropsychiatric inventory. 
*n=403. †UK qualifications are broken down into academic advanced levels 
(A levels or equivalent, post compulsory education), higher secondary education 
(O levels, GCSEs, or equivalent), secondary education, and vocational 
qualifications (NVQ or equivalent). ‡n=399. §n=401. ¶n=400. ||n=398. 
**Calculated as frequency × severity.
Table 1: Baseline characteristics of care home residents
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cost-effective at a willingness to pay of £30 000. These 
results are conservative and should be interpreted with 
caution because resource use and utility values were not 
available for the additional residents considered to benefit 
from the intervention and, therefore, mean resource use 
costs and utility values of those allocated to receive the 
MARQUE intervention were used.
At 8 months, the number of deaths was not signifi-
cantly different between the two groups (27 [18%] of 
189 residents had died in the MARQUE group vs 41 [19%] 
of 215 residents in the TAU group; figure 1) and anti-
psychotic drug prescription rate was similar between the 
MARQUE and TAU groups (table 3).
Discussion
We designed, developed, and tested the MARQUE 
intervention using evidence from systematic reviews on 
what works, and how to sustain interventions, and in-
corporated qualitative data, based on interviews with care 
home staff about their experience of agitation and ideas 
about what was possible in a care home.11,17,23 We trained 
and supervised facilitators; the low intra cluster correlation, 
high attendance rates, and high fidelity scores indicate 
satisfactory delivery. The follow-up rate was high for 
resident measures and the majority of loss to follow-up was 
due to mortality. Despite successful delivery, the MARQUE 
intervention was not associated with a signifi cant improve-
ment in agitation, quality of life, a reduction in possibly 
abusive behaviours, or with staff reduction in burnout or 
improvement in sense of competence. This is the first trial 
to attempt the delivery of a pragmatic, scalable, and costed 
intervention. The intervention was designed to be scalable 
and affordable across UK care homes.
This trial has several limitations. The use of broad 
eligibility criteria for homes was designed to enhance 
external validity. However, consent was obtained for only 
around 60% of the residents assessed for eligibility, and 
for 177 residents with dementia who had a family carer, 
the family member could not be contacted and so these 
residents were not assessed, which highlights the 
possibility of recruitment bias. The facilitators noted that 
many residents who were discussed in training, and 
described as being the most agitated and whom they were 
told benefited greatly, were not included in the study. This 
suggests that the residents included might have been a 
more healthy population than residents who were not 
included. Correspondingly, more residents who had 
capacity to consent were included in the study than 
residents without capacity, suggesting our intervention 
population might have been biased in favour of residents 
with less severe cognitive impairment than residents who 
refused to participate and therefore the included residents 
probably had fewer symptoms of agitation than residents 
in care homes overall.6
The residents randomly assigned to the MARQUE 
group had less severe dementia than the population in a 
similar trial,12 in which 90% had moderate or severe 
dementia. Similarly, although all staff attended training, 
the staff recruited to the study reported high levels of self-
assessed competence at baseline and had higher personal 
accomplishment and lower depersonalisation scores on 
the burnout scale than did care home staff in general.42
We planned to analyse cost-effectiveness, which is 
important in the UK because it informs the National 
Institute for Health and Care Excellence (NICE) guidelines. 
The fact that the cost of MARQUE was not found to be 
significantly less than TAU might be explained by the fact 
that cost data has higher variance than effect data and the 
study was powered for the primary outcome. Clinical 
evaluation literature suggest that the aim of economic 
evaluation should be the estimation of a parameter 
(ie, incremental cost-effectiveness) with appropriate 
representation of uncertainty, rather than hypothesis 
testing and we reported the estimated uncertainty in cost-
effectiveness results rather than tests of hypotheses.
Treatment as 
usual (n=249)
MARQUE 
(n=243)
Sex
Men 38/248 (15%) 32 (13%)
Women 210/248 (85%) 211 (87%)
Age (years)* 44 (13) 43 (12)
Ethnicity
White 112/248 (45%) 74/241 (31%)
Asian 37/248 (15%) 39/241 (16%)
Black 85/248 (34%) 104/241 (43%)
Other 14/248 (6%) 24/241 (10%)
First language English 124/248 (50%) 115/242 (48%)
Time working in a care home 
(years)†
6 (2–13) 7 (2–12)
Time working in this care home 
(years)‡
2 (1–7) 2 (1–6)
Working as a qualified nurse in care 
home
27/249 (11%) 31/242 (13%)
Maslach Burnout Inventory
Emotional exhaustion score§ 19 (12) 16 (12)
Personal accomplishment score¶ 41 (7) 41 (7)
Depersonalisation score|| 3 (4) 3 (4)
Sense of Competence in Dementia
Total** 58 (6) 57 (6)
Professionalism†† 18 (2) 18 (2)
Building relationships‡‡ 13 (2) 13 (2)
Care challenges§§ 13 (2) 13 (2)
Sustaining personhood‡ 14 (2) 14 (2)
Staff Tactics Scale
Any abusive behaviour (at least 
sometimes)
116/242 (48%) 124/234 (53%)
Any positive behaviour (never or 
almost never)
72/238 (30%) 84/232 (36%)
Data are n (%), n/N (%), mean (SD), or median (IQR). Denominators for the care 
staff vary because not all staff completed all assessments. *n=478. †n=484. 
‡n=481. §n=462. ¶n=453. ||n=471. **n=461. ††n=482. ‡‡n=480. §§n=476.
Table 2: Baseline characteristics of care home staff
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Although the study was not powered to investigate 
changes in possible abuse scores and prescription of 
antipsychotic drugs, abuse scores decreased by around a 
third in the intervention group (reduction in abuse scores 
2% in the TAU group vs 14% in the MARQUE group) 
and antipsychotic prescribing remained stable, which 
suggests that care practices and management strategies 
were changing. Considering the long-term nature of the 
study, it is possible that more differences between groups 
would have emerged as the intervention became part of 
culture over time.
Within MARQUE, we attempted to integrate strategies 
promoting change into routine care practices and for 
the successful strategies to be embedded—eg, by 
Treatment as usual 
(n=163)
MARQUE (n=155) Mean difference (95% CI)* p value
CMAI
CMAI score† 44 (17) 42 (16) –0·40 (–3·89 to 3·09); N=296 0·8226
Clinically significant agitation 
(CMAI >45)
55 (34%) 49 (32%) 1·14‡ (0·61 to 2·12); N=296 0·6828
NPI
NPI score 16 (14), n=166 14 (16) –0·84 (–5·51 to 3·84); N=299 0·7260
NPI agitation§ 2 (3) 2 (3) 0·22 (–0·54 to 0·98); N=299 0·5647
NPI agitation 87/167 (52%) 81 (52%) 1·04‡ (0·61 to 1·80); N=318 0·8788
DEMQOL
Staff proxy 104 (12), n=165 104 (12), n=154 0·09 (–3·87 to 4·05); N=298 0·9657
Family carer proxy 99 (13), n=117 100 (15), n=100 –0·03 (–2·87 to 2·82); N=205 0·9859
Psychotropic drugs
Any psychotropic drugs 78/165 (47%) 66/152 (43%) 1·20‡¶ (0·61 to 2·39); N=316 0·5970
Antipsychotics 21/165 (13%) 15/152 (10%) 0·66‡¶ (0·26 to 1·69); N=316 0·3880
Antidepressants 57/165 (35%) 50/152 (33%) 1·49‡¶ (0·65 to 3·40); N=316 0·3475
Anxiolytics or hypnotics 21/165 (13%) 16/152 (11%) 0·92‡¶ (0·34 to 2·48); N=316 0·8707
Data are mean (SD), n (%), or n/N (%). The number of observations differ due to missing data. Treatment effect estimates were derived from hierarchical mixed models. 
The number of patients included in the hierarchical mixed models do not sum to the total number of patients due to missing covariate and outcome data. 
Patient denominators for secondary outcomes in the treatment as usual group exceed 163 because these analyses included residents for whom primary outcome data was 
not available, but data on medication was available at 8 months. CMAI=Cohen-Mansfield Agitation Inventory. N=number of patients included in the hierarchical mixed 
models. NPI=Neuropsychiatric Inventory. *Adjusted for baseline score (or caseness as appropriate), type of care home (residential only vs others), and dementia severity 
(Clinical Dementia Rating). †Sensitivity analyses for primary outcome: mean difference –2·08 (95% CI –7·14 to 2·97) for unadjusted analysis; –1·65 (–5·24 to 1·95) adjusted for 
predictors of missingness (age, sex, family carer sex); and –1·13 (–4·89 to 2·63) adjusted for baseline imbalances (sex, marital status, any psychotropic drugs). ‡Odds ratio. 
§Calculated as frequency × severity. ¶Adjusted for outcome caseness at baseline.
Table 3: Resident outcomes at 8 months
Treatment as usual 
(n=179)
MARQUE  
(n=175)
Mean difference  
(95% CI)*
p value
Maslach Burnout Inventory
Emotional exhaustion 18 (13), n=175 18 (13), n=169 0·50 (–1·89 to 2·89); N=326 0·6816
Personal accomplishment 42 (7), n=173 41 (7), n=167 –0·55 (–2·23 to 1·13); N=314 0·5243
Depersonalisation 2 (3), n=175 3 (4), n=170 0·61 (–0·06 to 1·29); N=332 0·0746
Sense of Competence in Dementia
Overall 60 (6), n=170 59 (7), n=168 –0·65 (–2·10 to 0·80); N=320 0·3806
Professionalism 18 (2), n=173 18 (2), n=173 –0·21 (–0·60 to 0·19); N=340 0·2999
Building relationships 14 (2), n=174 13 (2), n=173 –0·14 (–0·66 to 0·38); N=340 0·5944
Care challenges 14 (2), n=172 13 (2), n=172 –0·16 (–0·64 to 0·32); N=335 0·5089
Sustaining personhood 14 (2), n=172 14 (2), n=173 –0·21 (–0·56 to 0·15); N=336 0·2623
Staff Tactics Scale
Any abusive behaviour (at least sometimes) 82/178 (46%) 69/178 (39%) 0·67† (0·43 to 1·05); N=356 0·0790
Any positive behaviour (never or almost never) 33/178 (19%) 43/173 (25%) 0·78† (0·43 to 1·43); N=356 0·4249
Data are mean (SD) or n (%). The number of observations differ due to missing data. The number of care home staff included in the hierarchical mixed models do not sum to 
the total number of care home staff due to missing covariate and outcome data. N=number of care home staff included in the hierarchical mixed models. *Adjusted for 
baseline score and type of care home (residential only vs nursing or mixed nursing or residential). †Odds ratio, adjusted for percentage at baseline aggregated by care home 
and type of care home (residential only vs others).
Table 4: Care home staff outcomes at 8 months
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encouraging reflective practice, co-creation of SMART 
action plans, training champions, and offering follow-up 
supervision and support.
Three studies10,12,13 have reported clinically significant 
reductions in agitation in care homes. These inter-
ventions were intensive and multicomponent, 
combining the following elements: staff training; 
increased social interaction; antipsychotic review; 
physician review of medical history and medications; 
assessment of pain; a doctor and nurse-led reflective 
case conference develop ing individualised treatment 
plans; a 3 h educational lecture; staff role play; 45 min 
sessions of activity therapy for residents delivered twice 
a week; and training of care home staff by a doctor and 
nurse in two 4 h blocks. Few data are available on the 
cost of these time and resource intensive inter ventions 
and no data are available on their cost-effectiveness 
or whether it might be possible to deliver such 
interventions nationwide to the population at risk in 
care homes. Questions will always remain about 
whether less expensive and less intensive alternatives 
are as effective, or almost as effective, as time and 
resource-intensive interventions, so this study is a 
valuable contribution to knowledge. The MARQUE 
intervention represents a less intensive training inter-
vention that was interactive, in which staff were asked 
to put ideas into practice and report on their effects, 
with ongoing support for staff to implement changes. 
The intervention was not delivered by experienced 
clinicians because they are scarce and costly.
Our economic analyses showed the intervention is 
cost-effective since the mean incremental cost per QALY 
gained of £14 064 is less than the NICE threshold of 
£20 000, but with a relatively low probability (62%) 
of being cost-effective at a willingness to pay of 
£20 000 per QALY. The results are driven by assumptions 
about the cost of the intervention, and the sensitivity 
analysis suggests implementation on the basis of quality 
of life should be interpreted with caution.
The paucity of evidence for the effectiveness of the 
intervention for agitation, coupled with the economic 
analysis, indicates that the implementation of MARQUE 
should not be recommended on the basis of differences 
in costs, QALYs, or cost-effectiveness.
This study does not support the MARQUE intervention 
being implemented in care homes and suggests higher 
intensity interventions are required for people with 
agitation in care homes. These interventions would be 
delivered by professional staff with whole-home manage-
ment and cultural change, implementing social and 
activity times with residents who are agitated, with a 
longer time period in which to implement change. The 
possible decrease in abuse and antipsychotic prescribing 
in addition to the cost-effectiveness data indicates 
that lower intensity, less costly interventions have the 
potential to improve some aspects of life for care home 
residents and care practices.
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